Ovarian cancer breakthrough: the potential of rhenium tricarbonyl (TRIP) as a promising anti-tumour drug
In this exclusive article, Drug Target Review’s Izzy Wood highlights…
In this exclusive article, Drug Target Review’s Izzy Wood highlights ground-breaking ovarian cancer research, after speaking with Dr Benjamin Neuditschko, from the Institute Krems Bioanalytics at IMC Krems.